Share on StockTwits

Equities research analysts at M Partners assumed coverage on shares of Antibe Therapeutics (CVE:ATE) in a research note issued to investors on Wednesday. The firm set a “buy” rating and a C$1.30 price target on the stock. M Partners’ price target indicates a potential upside of 160.00% from the stock’s previous close.

Antibe Therapeutics Inc develops and out-licenses protected new pharmaceuticals. The Company’s drug design methodologies involve chemically linking an existing drug (CVE:ATE) to an Antibe-patented, hydrogen sulfide-releasing molecule; hydrogen sulfide (H2S) is the key gaseous mediators and has anti-inflammatory, anti-nociceptive (pain-killing) and vasodilatory properties.

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.